Real-World Acute Toxicity and 90-Day Mortality in Patients With Stage I NSCLC Treated With Stereotactic Body Radiotherapy.

Autor: van Rossum PSN; Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands. Electronic address: p.s.n.vanrossum@amsterdamumc.nl., Wolfhagen N; Dutch Institute for Clinical Auditing, Leiden, The Netherlands; Department of Cardiothoracic Surgery, Radboud University Medical Center, Nijmegen, The Netherlands., van Bockel LW; Department of Radiation Oncology, Haga Hospital, The Hague, The Netherlands., Coremans IEM; Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands., van Es CA; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Geest AM; Radiotherapy Institute Friesland, Leeuwarden, The Netherlands., De Jaeger KEA; Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands., Wachters B; Southwest Radiotherapy Institute, Vlissingen and Roosendaal, The Netherlands., Knol HP; Department of Radiation Oncology, Northwest Hospital Group, Alkmaar, The Netherlands., Koppe FLA; Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands., Pomp J; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Reymen BJT; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands., Schinagl DAX; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Spoelstra FOB; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands., Tissing-Tan CJA; Radiotherapy Group, Institute for Radiation Oncology, Arnhem, The Netherlands., Peters M; Radiotherapy Group, Institute for Radiation Oncology, Deventer, The Netherlands., van der Voort van Zijp NCMG; Department of Radiation Oncology, Haaglanden Medical Center, The Hague, The Netherlands., van der Wel AM; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, The Netherlands., Wiegman EM; Department of Radiation Oncology, Isala Oncology Center, Zwolle, The Netherlands., Wijsman R; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Damhuis RAM; Department of Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands., Belderbos JSA; Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Nov; Vol. 19 (11), pp. 1550-1563. Date of Electronic Publication: 2024 Jul 25.

The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis.

Autor: Ronden MI; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands.; Department of Pulmonology, Amsterdam UMC, Amsterdam, the Netherlands., Bahce I; Department of Pulmonology, Amsterdam UMC, Amsterdam, the Netherlands., Claessens NJM; Department of Pulmonology, Rijnstate Ziekenhuis, Arnhem, the Netherlands., Barlo N; Department of Pulmonology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands., Dahele MR; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands., Daniels JMA; Department of Pulmonology, Amsterdam UMC, Amsterdam, the Netherlands., Tissing-Tan C; Radiotherapy Group, Institute for Radiation Oncology, Arnhem, the Netherlands., Hekma E; Department of Surgery, Rijnstate Ziekenhuis, Arnhem, the Netherlands., Hashemi SMS; Department of Pulmonology, Amsterdam UMC, Amsterdam, the Netherlands., van der Wel A; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands., Spoelstra FOB; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands., Verbakel WFAR; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands., Tiemessen MA; Department of Pulmonology, Dijklander Ziekenhuis, Hoorn & Purmerend, the Netherlands., van Laren M; Department of Pulmonology, Dijklander Ziekenhuis, Hoorn & Purmerend, the Netherlands., Becker A; Department of Pulmonology, Amsterdam UMC, Amsterdam, the Netherlands., Tarasevych S; Department of Pulmonology, Zaans Medisch Centrum, Zaandam, the Netherlands., Haasbeek CJA; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands., Maassen van den Brink K; Department of Pulmonology, Dijklander Ziekenhuis, Hoorn & Purmerend, the Netherlands., Dickhoff C; Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands., Senan S; Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2021 Jun 06; Vol. 2 (7), pp. 100195. Date of Electronic Publication: 2021 Jun 06 (Print Publication: 2021).

Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors.

Autor: Finazzi T; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands. Electronic address: t.finazzi@amsterdamumc.nl., Haasbeek CJA; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Spoelstra FOB; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Palacios MA; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Admiraal MA; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Bruynzeel AME; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Slotman BJ; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Lagerwaard FJ; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands., Senan S; Department of Radiation Oncology, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2020 Jun 01; Vol. 107 (2), pp. 270-278. Date of Electronic Publication: 2020 Feb 24.

Stereotactic ablative radiotherapy in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease.

Autor: Finazzi T; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Ronden-Kianoush MI; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Spoelstra FOB; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Nossent EJ; Department of Pulmonary Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Nijman SFM; Department of Pulmonary Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Bahce I; Department of Pulmonary Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Dickhoff C; Department of Surgery and Cardiothoracic Surgery, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Senan S; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Publikováno v: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2020 May; Vol. 59 (5), pp. 569-573. Date of Electronic Publication: 2020 Feb 20.

A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.

Autor: Bruynzeel AME; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. Electronic address: ame.bruynzeel@vumc.nl., Tetar SU; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Oei SS; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Senan S; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Haasbeek CJA; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Spoelstra FOB; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Piet AHM; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Meijnen P; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Bakker van der Jagt MAB; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Fraikin T; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Slotman BJ; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., van Moorselaar RJA; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Lagerwaard FJ; Department of Radiation Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2019 Dec 01; Vol. 105 (5), pp. 1086-1094. Date of Electronic Publication: 2019 Aug 13.